|
1
|
Faix JD: Biomarkers of sepsis. Crit Rev
Clin Lab Sci. 50:23–36. 2013.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Huang M, Cai S and Su J: The pathogenesis
of sepsis and potential therapeutic targets. Int J Mol Sci.
20(5376)2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Martin GS: Sepsis, severe sepsis and
septic shock: Changes in incidence, pathogens and outcomes. Expert
Rev Anti Infect Ther. 10:701–706. 2012.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Rossaint J and Zarbock A: Pathogenesis of
multiple organ failure in sepsis. Crit Rev Immunol. 35:277–291.
2015.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Huang CT, Tsai YJ, Tsai PR, Yu CJ and Ko
WJ: Epidemiology and outcome of severe sepsis and septic shock in
surgical intensive care units in Northern Taiwan. Medicine
(Baltimore). 94(e2136)2015.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Martinez A and Gil C: cAMP-specific
phosphodiesterase inhibitors: Promising drugs for inflammatory and
neurological diseases. Expert Opin Ther Pat. 24:1311–1321.
2014.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Lynch MJ, Hill EV and Houslay MD:
Intracellular targeting of phosphodiesterase-4 underpins
compartmentalized cAMP signaling. Curr Top Dev Biol. 75:225–259.
2006.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Ioakeimidis N and Kostis JB: Pharmacologic
therapy for erectile dysfunction and its interaction with the
cardiovascular system. J Cardiovasc Pharmacol Ther. 19:53–64.
2014.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Peng T, Qi B, He J, Ke H and Shi J:
Advances in the development of phosphodiesterase-4 inhibitors. J
Med Chem. 63:10594–10617. 2020.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Di Luigi L, Sansone M, Sansone A, Ceci R,
Duranti G, Borrione P, Crescioli C, Sgrò P and Sabatini S:
Phosphodiesterase type 5 inhibitors, sport and doping. Curr Sports
Med Rep. 16:443–447. 2017.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Xu M, Yu X, Meng X, Huang S, Zhang Y,
Zhang A and Jia Z: Inhibition of PDE4/PDE4B improves renal function
and ameliorates inflammation in cisplatin-induced acute kidney
injury. Am J Physiol Renal Physiol. 318:F576–F588. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Sakkas LI, Mavropoulos A and Bogdanos DP:
Phosphodiesterase 4 inhibitors in immune-mediated diseases: Mode of
action, clinical applications, current and future perspectives.
Curr Med Chem. 24:3054–3067. 2017.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Myers SA, Gobejishvili L, Saraswat Ohri S,
Garrett Wilson C, Andres KR, Riegler AS, Donde H, Joshi-Barve S,
Barve S and Whittemore SR: Following spinal cord injury, PDE4B
drives an acute, local inflammatory response and a chronic,
systemic response exacerbated by gut dysbiosis and endotoxemia.
Neurobiol Dis. 124:353–363. 2019.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Feng H, Chen J, Wang H, Cheng Y, Zou Z,
Zhong Q and Xu J: Roflumilast reverses polymicrobial sepsis-induced
liver damage by inhibiting inflammation in mice. Lab Invest.
97:1008–1019. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chang X, Hu LF, Ma XJ, Yin J, Liu XY and
Li JB: Influence of roflumilast on sepsis mice through the JAK/STAT
signaling pathway. Eur Rev Med Pharmacol Sci. 23:1335–1341.
2019.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Xu X, Liao L, Hu B, Jiang H and Tan M:
Roflumilast, a phosphodiesterases-4 (PDE4) inhibitor, alleviates
sepsis-induced acute kidney injury. Med Sci Monit.
26(e921319)2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
El-Ashmawy NE, Khedr NF, El-Bahrawy HA and
El-Adawy SA: Roflumilast, type 4 phosphodiesterase inhibitor,
attenuates inflammation in rats with ulcerative colitis via
down-regulation of iNOS and elevation of cAMP. Int Immunopharmacol.
56:36–42. 2018.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408.
2001.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Stoller J, Halpin L, Weis M, Aplin B, Qu
W, Georgescu C and Nazzal M: Epidemiology of severe sepsis:
2008-2012. J Crit Care. 31:58–62. 2016.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Sertaridou E, Papaioannou V, Kolios G and
Pneumatikos I: Gut failure in critical care: Old school versus new
school. Ann Gastroenterol. 28:309–322. 2015.PubMed/NCBI
|
|
21
|
Yang H, Song Z, Jin H, Cui Y, Hou M and
Gao Y: Protective effect of rhBNP on intestinal injury in the
canine models of sepsis. Int Immunopharmacol. 19:262–266.
2014.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Deitch EA: Bacterial translocation or
lymphatic drainage of toxic products from the gut: What is
important in human beings? Surgery. 131:241–244. 2002.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Deitch EA, Xu D and Kaise VL: Role of the
gut in the development of injury- and shock induced SIRS and MODS:
The gut-lymph hypothesis, a review. Front Biosci. 11:520–528.
2006.PubMed/NCBI View
Article : Google Scholar
|
|
24
|
Li H, Fan C, Feng C, Wu Y, Lu H, He P,
Yang X, Zhu F, Qi Q, Gao Y, et al: Inhibition of
phosphodiesterase-4 attenuates murine ulcerative colitis through
interference with mucosal immunity. Br J Pharmacol. 176:2209–2226.
2019.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Kumar P, Nagarajan A and Uchil PD:
Analysis of cell viability by the lactate dehydrogenase assay. Cold
Spring Harb Protoc. 2018:2018.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Wolvekamp MC and de Bruin RW: Diamine
oxidase: An overview of historical, biochemical and functional
aspects. Dig Dis. 12:2–14. 1994.PubMed/NCBI View Article : Google Scholar
|
|
27
|
Derikx JP, Schellekens DH and Acosta S:
Serological markers for human intestinal ischemia: A systematic
review. Best Pract Res Clin Gastroenterol. 31:69–74.
2017.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Sakai M, Suzuki T, Tomita K, Yamashita S,
Palikhe S, Hattori K, Yoshimura N, Matsuda N and Hattori Y:
Diminished responsiveness to dobutamine as an inotrope in mice with
cecal ligation and puncture-induced sepsis: Attribution to
phosphodiesterase 4 upregulation. Am J Physiol Heart Circ Physiol.
312:H1224–H1237. 2017.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Gong S, Chen Y, Meng F, Zhang Y, Li C,
Zhang G, Huan W and Wu F: Roflumilast enhances
cisplatin-sensitivity and reverses cisplatin-resistance of ovarian
cancer cells via cAMP/PKA/CREB-FtMt signalling axis. Cell Prolif.
51(e12474)2018.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Takano A, Uz T, Garcia-Segovia J, Tsai M,
Lahu G, Amini N, Nakao R, Jia Z and Halldin C: A nonhuman primate
PET study: Measurement of brain PDE4 occupancy by roflumilast using
(R)-[11C]Rolipram. Mol Imaging Biol. 20:615–622.
2018.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Peng S, Yan HZ, Liu PR, Shi XW, Liu CL,
Liu Q and Zhang Y: Phosphodiesterase 4 inhibitor roflumilast
protects rat hippocampal neurons from sevoflurane induced injury
via modulation of MEK/ERK signaling pathway. Cell Physiol Biochem.
45:2329–2337. 2018.PubMed/NCBI View Article : Google Scholar
|
